Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Company Overview

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapeutics for the treatment of viral diseases and liver disorders. Headquartered in South San Francisco, California, Aligos is advancing a pipeline of both small molecule and nucleic acid-based programs designed to achieve functional cures or meaningful clinical improvements in patients with chronic hepatitis B virus (HBV) infection and nonalcoholic steatohepatitis (NASH).

The company’s research engine integrates cutting-edge chemistry, immunology and RNA biology to create targeted therapies that address multiple stages of the viral lifecycle and modulate host immune responses. Lead programs include orally administered inhibitors that target HBV replication and novel RNA interference (RNAi) assets aimed at silencing viral and fibrotic pathways in the liver. Preclinical candidates are also being evaluated for their potential to enhance antiviral immunity and reverse liver fibrosis in NASH patients.

Founded in 2014, Aligos has drawn on venture capital support and strategic partnerships to build its scientific platform and advance assets through clinical development. The company went public in 2020, listing its shares on the NASDAQ under the ticker ALGS. Since inception, Aligos has maintained a commitment to rigorous translational research, leveraging in-house manufacturing capabilities and external collaborations to optimize its drug candidates for safety, potency and delivery.

Aligos conducts its clinical trials across the United States, Europe and Asia, engaging leading medical centers and patient communities to generate robust data in diverse populations. The company is led by a team of seasoned biotechnology executives and scientific leaders with extensive experience in virology, hepatology and drug development. Together, they aim to deliver transformational therapies that address significant unmet needs in chronic liver disease and viral infection.

Key Stats

• Today's Range: $8.26 to $8.85
• 50-Day Range: $4.36 to $8.79
• 52-Week Range: $3.76 to $46.80
• Volume: 60,315 shs
• Average Volume: 213,631 shs
• Market Capitalization: $51.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $70.00
• Consensus Rating: Buy

Aligos Therapeutics Stock Analysis - MarketRank™

Aligos Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 201st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aligos Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aligos Therapeutics are expected to decrease in the coming year, from ($10.36) to ($11.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aligos Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aligos Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.63% of the float of Aligos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aligos Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aligos Therapeutics has recently decreased by 1.68%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aligos Therapeutics does not currently pay a dividend.

Dividend Growth

Aligos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.80

Percentage of Shares Shorted

12.63% of the float of Aligos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aligos Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aligos Therapeutics has recently decreased by 1.68%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

Aligos Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aligos Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Aligos Therapeutics is held by insiders.

Percentage Held by Institutions

60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed this year?

Aligos Therapeutics' stock was trading at $39.84 at the beginning of 2025. Since then, ALGS stock has decreased by 79.0% and is now trading at $8.36.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($2.11) EPS for the quarter, beating the consensus estimate of ($2.80) by $0.69. The company earned $0.31 million during the quarter, compared to analyst estimates of $0.33 million. Aligos Therapeutics had a positive trailing twelve-month return on equity of 14.67% and a negative net margin of 1,628.75%.

When did Aligos Therapeutics' stock split?

Shares of Aligos Therapeutics reverse split on Monday, August 19th 2024.The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aligos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Athenex (ATNX), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALGS
• CIK: 1799448
• Web: www.aligos.com
• Phone: 800-466-6059
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aligos Therapeutics: $70.00
• High Price Target: $70.00
• Low Price Target: $70.00
• Potential Upside/Downside: +737.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($17.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$131.21 million
• Net Margins: -1,628.75%
• Pretax Margin: -1,618.04%
• Return on Equity: 14.67%
• Return on Assets: 7.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.56
• Quick Ratio: 7.56

Sales & Book Value

• Annual Sales: $3.94 million
• Price / Sales: 12.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.50) per share
• Price / Book: -1.11

Miscellaneous

• Outstanding Shares: 6,110,000
• Free Float: 5,821,000
• Market Cap: $51.08 million
• Optionable: No Data
• Beta: 2.77